GlassScriptPhysician profile
Amber Tate
NPI 1043763410
$13,012.94
in general payments reported to CMS, 2019-2025
24 companies · $2,455 in 2025
The $2,455 reported for 2025 was more than what 95% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,199 · 2022: $3,282 · 2023: $2,459 · 2024: $2,618 · 2025: $2,455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,483 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,483.34 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,899.21 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,892.34 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $1,458.59 | 2021-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,386.69 | 2021-2025 | Caplyta |
| Alkermes, INC. | $900.56 | 2022-2025 | Aristada, Lybalvi |
| Corium, LLC | $858.51 | 2022-2025 | Azstarys |
| Lundbeck LLC | $718.79 | 2021-2025 | Rexulti, Abilify Asimtufii |
| Takeda Pharmaceuticals U.S.A., INC. | $706.29 | 2021-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $674.99 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $545.57 | 2021-2024 | Spravato, Invega Sustenna, Invega |
| Sunovion Pharmaceuticals INC. | $422.53 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $341.69 | 2024-2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $264.94 | 2021-2025 | Qelbree, Qelbree |
| Tris Pharma INC | $202.97 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $162.37 | 2025 | Jornay Pm |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $134.86 | 2022-2024 | Auvelity |
| Ironshore Pharmaceuticals INC. | $109.02 | 2022-2024 | Jornay Pm |
| Neos Therapeutics, LP | $77.88 | 2023-2024 | Adzenys Xr-Odt |
| Avanir Pharmaceuticals, INC. | $71.12 | 2021-2022 | |
| Tempus Ai, INC | $67.36 | 2024 | |
| Idorsia Pharmaceuticals US INC | $51.67 | 2022-2023 | Quviviq |
| Jazz Pharmaceuticals INC. | $37.67 | 2021 | |
| Biogen, INC. | $16.09 | 2024 | |
| Eisai INC. | $11.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Tate listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.